+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Foot Ulcers (Metabolic Disorder) - Drugs in Development, 2021

  • PDF Icon

    Report

  • 218 Pages
  • October 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5473058
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2021, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape. Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights


This pipeline guide provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 20, 10, 2, 17, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders)
  • The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
Diabetic Foot Ulcers - Overview
  • Diabetic Foot Ulcers - Therapeutics Development
  • Diabetic Foot Ulcers - Therapeutics Assessment
  • Diabetic Foot Ulcers - Companies Involved in Therapeutics Development
  • Diabetic Foot Ulcers - Drug Profiles
  • Diabetic Foot Ulcers - Dormant Projects
  • Diabetic Foot Ulcers - Discontinued Products
  • Diabetic Foot Ulcers - Product Development Milestones

Appendix
List of Tables
  • Number of Products under Development for Diabetic Foot Ulcers, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Diabetic Foot Ulcers - Pipeline by Alan Laboratories Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Anterogen Co Ltd, 2021
  • Diabetic Foot Ulcers - Pipeline by Aposcience AG, 2021
  • Diabetic Foot Ulcers - Pipeline by Aprogen Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by APstem Therapeutics Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by AptaBio Therapeutics Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Aurealis Therapeutics AG, 2021
  • Diabetic Foot Ulcers - Pipeline by Beijing Huafeng Biotechnology Co Ltd, 2021
  • Diabetic Foot Ulcers - Pipeline by Biofilm Pharma, 2021
  • Diabetic Foot Ulcers - Pipeline by Blue Blood Biotech Corp, 2021
  • Diabetic Foot Ulcers - Pipeline by Canton Biotechnologies Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Cellics Therapeutics Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Cellresearch Corp Pte Ltd, 2021
  • Diabetic Foot Ulcers - Pipeline by Celularity Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Chiesi Farmaceutici SpA, 2021
  • Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by Crescita Therapeutics Inc, 2021
  • Diabetic Foot Ulcers - Pipeline by CSA Biotechnologies LLC, 2021
  • Diabetic Foot Ulcers - Pipeline by cStem Regeneration Pharmaceutical Co Ltd, 2021
  • Diabetic Foot Ulcers - Dormant Projects, 2021
  • Diabetic Foot Ulcers - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Diabetic Foot Ulcers, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alan Laboratories Inc
  • Anterogen Co Ltd
  • Aposcience AG
  • Aprogen Inc
  • APstem Therapeutics Inc
  • AptaBio Therapeutics Inc
  • Aurealis Therapeutics AG
  • Beijing Huafeng Biotechnology Co Ltd
  • Biofilm Pharma
  • Blue Blood Biotech Corp
  • Canton Biotechnologies Inc
  • Cellics Therapeutics Inc
  • Cellresearch Corp Pte Ltd
  • Celularity Inc
  • Chiesi Farmaceutici SpA
  • Chrysalis BioTherapeutics Inc
  • Crescita Therapeutics Inc
  • CSA Biotechnologies LLC
  • cStem Regeneration Pharmaceutical Co Ltd
  • Cynata Therapeutics Ltd
  • CytoTools AG
  • Destiny Pharma Plc
  • Energenesis Biomedical Co Ltd
  • Genentech USA Inc
  • Health & Biotech Co Ltd
  • Helixmith Co Ltd
  • Hoth Therapeutics Inc
  • Human Stem Cells Institute
  • Lakewood-Amedex Inc
  • Liminal BioSciences Inc
  • Madam Therapeutics BV
  • Mallinckrodt Plc
  • MangoGen Pharma Inc
  • MediWound Ltd
  • Mirae Cell Bio Co Ltd
  • NovaLead Pharma Pvt Ltd
  • OliX Pharmaceuticals Inc
  • Orbsen Therapeutics Ltd
  • Perpetuum BV
  • Pherecydes Pharma SA
  • Promore Pharma AB
  • Qilu Pharmaceutical Co Ltd
  • Remedor Biomed Ltd
  • RHEACELL GmbH & Co KG
  • Riptide Bioscience Inc
  • SaNOtize Research and Development Corp
  • Scarless Laboratories Inc
  • Serodus ASA
  • Shionogi & Co Ltd
  • Stempeutics Research Pvt Ltd
  • TechnoPhage SA
  • TGV-Inhalonix Inc
  • Therapeutic Systems Research Laboratories Inc
  • Tissuetech Inc
  • Topadur Pharma AG
  • Transwell Biotech Co Ltd
  • USV Pvt Ltd
  • Vasomune Inc
  • Venturis Therapeutics Inc
  • Xenexus Pharmaceuticals Pty Ltd
  • Zhittya Genesis Medicine Inc
  • ZZ Biotech LLC